- Tytuł:
- Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
- Autorzy:
- Źródło:
- Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 41(3):380-390
Czasopismo naukowe